Parameter
| Biomarker | ELOVL7 / SOCS3 / ACSL4 / CLU / PRKAR1A / ABCG1; cg26345888 / DAB1; Flavonifractor plautii; Phytosphingosine; ApoA2 / ACE-2 / IL-33 / FoxP3 | Full name | / | Molecular Type | Gene expression / mRNA; DNA methylation / Epigenetic; Gut microbiome; Metabolite; Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Constitution identification, early warning, metabolic-risk assessment, vascular endothelial function assessment |
| Disease | Phlegm-dampness constitution (PDC) | Disease Subtypes | / | ||
| Organ | Intestine; vascular system; gut–liver axis | Test Sample / Technology Platform | PBMCs (gene-expression microarray, qRT-PCR, pyrosequencing); feces (metagenomic sequencing, qPCR); serum (proteomics, metabolomics, LC-MS/MS); EndoPAT | ||
| Pathobiological Mechanisms | PDC is associated with abnormalities in metabolic and inflammatory regulation. Differential gene expression and DNA methylation are linked to metabolic susceptibility; reduced F. plautii and phytosphingosine are associated with higher PDC scores and metabolic abnormalities; altered ApoA2, ACE-2, IL-33 and FoxP3 are associated with impaired vascular endothelial function. | ||||
| Clinical Availability Status | Research-stage | ||||
| Notes and Dynamics | Representative biomarkers span transcriptomic, epigenetic, microbiome, metabolomic and proteomic levels. Some changes, particularly reduced F. plautii and phytosphingosine, were observed even in PDC individuals with normal metabolic indices, suggesting potential value for early risk assessment. | ||||